| Literature DB >> 34821690 |
Astha Khanna1, Maedeh Zamani2,3, Ngan F Huang2,3,4,5.
Abstract
Regenerative medicine and tissue engineering strategies have made remarkable progress in remodeling, replacing, and regenerating damaged cardiovascular tissues. The design of three-dimensional (3D) scaffolds with appropriate biochemical and mechanical characteristics is critical for engineering tissue-engineered replacements. The extracellular matrix (ECM) is a dynamic scaffolding structure characterized by tissue-specific biochemical, biophysical, and mechanical properties that modulates cellular behavior and activates highly regulated signaling pathways. In light of technological advancements, biomaterial-based scaffolds have been developed that better mimic physiological ECM properties, provide signaling cues that modulate cellular behavior, and form functional tissues and organs. In this review, we summarize the in vitro, pre-clinical, and clinical research models that have been employed in the design of ECM-based biomaterials for cardiovascular regenerative medicine. We highlight the research advancements in the incorporation of ECM components into biomaterial-based scaffolds, the engineering of increasingly complex structures using biofabrication and spatial patterning techniques, the regulation of ECMs on vascular differentiation and function, and the translation of ECM-based scaffolds for vascular graft applications. Finally, we discuss the challenges, future perspectives, and directions in the design of next-generation ECM-based biomaterials for cardiovascular tissue engineering and clinical translation.Entities:
Keywords: extracellular matrix (ECM); regenerative medicine; tissue engineering
Year: 2021 PMID: 34821690 PMCID: PMC8622600 DOI: 10.3390/jcdd8110137
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Figure 1Anatomy of large and small blood vessels. Reprinted from Stratman et al. [21]. “Chapter 24-Blood Vessel Formation” from Principles of Developmental Genetics (Second Edition), with permission from Elsevier.
Effect of ECM-based biomaterials on cardiovascular lineages.
| ECM | ECM-Based Biomaterials | Model | Cardiovascular Tissue Engineering Advantages | Ref. |
|---|---|---|---|---|
| Collagen | COL I | Murine | Cardiomyocyte differentiation, maturation and contractile function | [ |
| Collagen | ESC and iPSC/COL IV | In vitro | Differentiation of induced pluripotent stem cells (iPSs) into cardiomyocytes of contractile function. | [ |
| Collagen and Fibrin | COL 1/Fibrin | In vitro | Improved physical property, cardiac tissue compaction | [ |
| Collagen and Elastin | COL 1/Elastin | In vitro | Enhanced elasticity, maturation of valve interstitial cells and valve ECs. | [ |
| Fibrin | Fibrin | In vitro | Cardiomyocyte proliferation and cardiac regeneration | [ |
| Collagen | COL 1/Growth factors/MatrigelTM | In vitro | Cardiomyocyte differentiation and maturation | [ |
| HA | HA | In vitro | Attenuates cardiac fibrosis and promote cardiac muscle tissue regeneration | [ |
Abbreviations: ESC (embryonic stem cell); iPSC (induced pluripotent stem cell); COL 1 (collagen I); COL4 (collagen IV); EC (endothelial cell); HA (hyaluronic acid).
Decellularized ECM-based biomaterials and cardiovascular response.
| Tissue/Organ | Decellularization Method | Model | Vascular Response | Ref. |
|---|---|---|---|---|
| Adult | Pulsatile retrograde aortic perfusion | Porcine | Chicken cardiomyocytes were cultured. ECM retained collagen, elastin, glycosaminoglycans, and mechanical integrity. | [ |
| Porcine | Perfusion of Trypsin/EDTA and Triton-X100/deoxycholic acid (DCA) | Porcine | ECM retained elastin, collagen, and proteoglycan | [ |
| Rat Heart Adult | Three decellularization solutions were used: | In vitro | C2C12 myoblasts were seeded in vitro. ECM retained laminin in all groups, elastin in groups 1 and 2, collagen in groups 1 and 3. | [ |
| Porcine Aortic Valves | Triton X-100 | In vitro | ECs were seeded. EC mediated ECM deposition was observed. | [ |
| Human | SDS treatment | In vitro/In vivo | In vitro EC cell seeding and implantation in rats. EC culture growth was sustained for 8 weeks, ECM preserved. | [ |
| Tissue | SDS | In vitro/Porcine | Pre-seeding of EC progenitor cells and implantation in porcine carotid artery. No clotting observed. No signs of intimal hyperplasia. | [ |
| Bioartificial Tissue Engineered Heart | Coronary perfusion-based whole organ decellularization | In vitro/rat model | Recellularization with neonatal cardiac cells and rat aortic ECs. Constructs exhibited contractile function and EC culture growth. | [ |
| Neonatal Mouse Heart | Liquid nitrogen, erythrocyte lysis, and DNA/RNA removal | In vivo model of acute MI | nmECM showed improved heart function compared to adult heart derived ECM, cardiac repair after MI | [ |
| Cardiac | SDS | In vitro | cdECM promotes human cardiac fibroblast culture and human iPSC-derived cardiomyocytes. | [ |
| Porcine Cardiac Tissue | SDS | In vivo | Decellularized porcine myocardial extracellular matrix (dECM)-reduced graphene oxide hydrogel promoted increased expression of genes that regulated contractile function. | [ |
| Porcine Heart | SDS | In vitro | Enhanced maturation of cardiomyocytes (isolated from neonatal rats) in hdECM | [ |
| Rat Heart | Ionic and non-ionic detergents | In vivo | (AdMSCs) promoted increased cardiomyocyte-specific gene expression for 2–4 weeks. | [ |
Abbreviations: SDS (sodium dodecyl sulfate); EC (endothelial cells); ECM (extracellular matrix); DCA (deoxycholic acid); MI (myocardial Infarction); nmECM (ECM derived from neonatal mouse hearts); cdECM (cardiac decellularized ECM); iPSC (induced pluripotent stem cell); dECM (decellularized ECM); hd ECM (heart tissue-derived ECM); (AdMSCs) adipose tissue-derived mesenchymal stem cells.
ECM-mediated endothelial differentiation and function.
| ECM Component | Model | Endothelial Cell Response | Ref. |
|---|---|---|---|
| Laminin | In vitro | Differentiation of embryonic stem cells into functional endothelial progenitor cells. | [ |
| Laminin | In vitro | Laminin facilitates in vitro 3D vascular network formation by promoting uptake of VEGF by ECs. | [ |
| COL IV- multi-component ECM | In vitro | Improved endothelial differentiation of human induced pluripotent stem cells. | [ |
| Fibronectin | In vitro | EC growth and proliferation was supported by fibronectin coating on vascular grafts. | [ |
| RGD-modified HA | In vivo | EC migration and proliferation, formation of functional vasculature | [ |
| dECM | In vitro | endothelial progenitor cells encapsulated in blood vessel-derived dECM exhibited higher proliferation capability and enhanced vascular network formation. | [ |
| dECM | In vitro | In vitro EC cell seeding and implantation in rats. EC culture growth was sustained for 8 weeks, ECM preserved. | [ |
| dECM | In vivo | Hybrid ECM promoted proliferation and migration of HUVECs, significantly inhibited immune response and calcification, exhibited stability and biocompatibility compared to non-hybrid leaflet. | [ |
| Heparin | In vitro | Surfaces covalently immobilized with heparin promoted endothelial cell growth and inhibited SMCs. | [ |
| Fb/COL/LA/FN | In vitro | High EC cell densities were achieved in 7 days of culture | [ |
| Fibrin Fragment E (FbnE) | In vitro | Increased adhesion and endothelial differentiation. | [ |
| COL Coated PCL Membrane | In vitro | Continuous EC monolayer was observed on collagen coated membrane. ECs exhibited filopodia protruding from lamellipodia in the junctional areas on the collagen-coated membranes. | [ |
| Matrigel Matrix Comprising of LA, COL IV, Heparen Sulfate Proteoglycans | Ischemic mouse model | Improved neovasculature formation, promote cell growth, proliferation and differentiation of ECs. | [ |
| Cardiogel Composed of LA, FN and Interstitial COL I and IV | In vivo | ECM components promote growth of ECs and CMs, spontaneous contractile activity and phenotypic morphological differentiation. | [ |
Abbreviations: VEGF (vascular endothelial growth factor); EC (endothelial cells); ECM (extracellular matrix); DCA (deoxycholic acid); MI (myocardial Infarction); nmECM (ECM derived from neonatal mouse hearts); cdECM (cardiac decellularized ECM); iPSC (induced pluripotent stem cell); dECM (decellularized ECM); hd ECM (heart tissue-derived ECM); (AdMSCs) adipose tissue-derived mesenchymal stem cells; HA (hyaluronic acid); Fb (fibrin); LA (laminin); FN (fibronectin); COL (collagen); PCL (polycaprolactone).
Advantages and limitations of bioprinting techniques.
| 3D Bioprinting Technique | Advantages | Limitations | Ref. |
|---|---|---|---|
| Inkjet Bioprinting | Uses thermal, electromagnetic or piezoelectric technology to deposit droplets of “ink” (materials) | Low material viscosity (<10 Pa·s) and low droplet directionality. Lack of precision with respect to droplet size. Requirement for low viscosity bio-ink. Nozzle clogging and cellular distortion due to high-cell density. Low mechanical strength. Inability to provide continuous stream of material. | [ |
| Micro-Extrusion | Ability to print biomaterials with high cell densities (higher than 1 × 106 cells mL−1) comparable to physiological cell densities. Can produce continuous stream of material. Can successfully print high viscosity bio-inks such as polymers, clay-based substrates. | Low printing resolution (>100 µm) and slow printing speeds. Loss of cellular viability and distortion of cellular structure due to the pressure to expel the bio-ink. | [ |
| Laser-Assisted | Rapid printing speeds and ability to print biomaterials with wide range of viscosities (1–300 mPa/s). High degree of precision and resolution (1 cell/droplet). Can successfully print high density of cells 108 mL−1 | Time consuming: need to prepare reservoirs/ribbons. Lower cellular viability compared to other methods. Loss of cells due to thermal damage. SLA requires intense UV radiation for crosslinking process. Requires large amount of material. High cost. Long post processing time and fewer materials compatible with SLA. | [ |
Abbreviations: LIFT (laser-induced forward transfer); SLA (stereolithography SLA).
Cell-derived ECM strategies for engineering vascular grafts.
| Material | Treatment | Model | Vascular Graft Response | Ref. |
|---|---|---|---|---|
| PGA Scaffold | SMC | Bovine | Grafts exhibited goof vessel wall thickness, burst pressure, and collagen content. | [ |
| PGA Scaffold | SMC | Canine | Grafts exhibited good long-term patency for 8–10 weeks. | [ |
| PGA with Fibrinogen and Thrombin | SMC s and ECs derived from hiPSC | Porcine | Grafts exhibited endothelial differentiation. | [ |
| PGA Scaffold | MSCs | In vitro | Grafts exhibited superior mechanical properties and cellular growth. | [ |
| Fibrin Gel | Human fibroblast (hDFs) | Baboon | Grafts exhibited higher patency rates of >80%. | [ |
Abbreviations: SMC (smooth muscle cells); EC (endothelial cells); hiPSC (human induced pluripotent stem cells); hDF (human dermal fibroblast); MSC (mesenchymal stem cells); PGA (polyglycolic acid).
Two-dimensional scaffolds for vascular grafts.
| Material | Treatment | Model | Vascular Graft Response | Ref. |
|---|---|---|---|---|
| SIS | EC culture | In vitro | Grafts exhibited higher EC proliferation and cobblestone morphology. | [ |
| SIS | Pre-seeded with SMC and fibrinogen/thrombin | Porcine | Grafts exhibited endothelial cell attachment and graft patency. | [ |
| SIS | Heparin | Sheep | Grafts exhibited lumens with no sign of clotting or intimal hyperplasia. | [ |
| Pericardium | MSCs | Bovine | ECM and growth factors facilitated differentiation into ECs. | [ |
| Porcine SIS Tubes | Heparin/VEGF | Sheep | Grafts exhibited long term patency rates for 3 months with a confluent endothelium and no signs of thrombosis. | [ |
Abbreviations: SMC (smooth muscle cells); EC (endothelial cells); SIS (small intestine submucosa); MSC (mesenchymal stem cells); VEGF (vascular endothelial growth factor).
Cannular tissues for vascular grafts.
| Material | Treatment | Model | Vascular Graft Response | Ref. |
|---|---|---|---|---|
| Carotid Artery | Autologous EC | Porcine | Grafts exhibited patency rates of >90% for 6 months. | [ |
| Carotid Artery | MSCs | Porcine | ECM and growth factors cause differentiation of MSCs into ECs. | [ |
| Carotid Artery | Heparin | Porcine | Grafts exhibited lumens with no sign of clotting/thrombus. | [ |
| Carotid Artery | MSCs | Porcine | ECM and growth factors cause differentiation of MSCs into SMCs. | [ |
| Porcine Aorta | Autologous ECs | Canine | Grafts exhibited long term patency rates for 3 months. | [ |
| Aorta | Heparin/VEGF | Canine | Grafts exhibited patency of >90% post 2 years. | [ |
| Porcine Pericardium Scaffold | Fibrin mesh/Heparin/VEGF | Porcine | Grafts exhibited potential to accelerate in situ endothelialization. | [ |
Abbreviations: SMCs (smooth muscle cells); ECs (endothelial cells); MSCs (mesenchymal stem cells); VEGF (vascular endothelial growth factor).